Toripalimab plus nab-paclitaxel in metastatic or recurrent triple-negative breast cancer: a randomized phase 3 trialZefei Jiang, Yuan Sheng, Haibo Wang et al.|Nature Medicine|2024Cited by 121
Metronomic Capecitabine Plus Aromatase Inhibitor as Initial Therapy in Patients With Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Metastatic Breast Cancer: The Phase III MECCA TrialRuoxi Hong, Shusen Wang, Fei Xu et al.|Journal of Clinical Oncology|2025Cited by 12
LEONARDA-1: Phase III randomized study of lerociclib plus fulvestrant in patients with HR+, HER2- locally advanced or metastatic breast cancer that has progressed on prior endocrine therapy.Binghe Xu, Qingyuan Zhang, Yang Luo et al.|Journal of Clinical Oncology|2023Cited by 4
A plain language summary of results from the TORCHLIGHT trial of toripalimab plus chemotherapy for metastatic or recurrent triple-negative breast cancerYuan Sheng, Quchang Ouyang, Tao Sun et al.|Future Oncology|2024Cited by 1